Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on AbCellera Biologics. The associated price target remains the same with $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to AbCellera’s strategic repositioning and upcoming clinical milestones. He highlights that management is successfully shifting the business from a broad discovery-partner model toward a more focused, internally owned pipeline, with ABCL635 as the lead asset targeting menopausal vasomotor symptoms and key Phase 1/2 data expected to begin reading out with the May 11 update and continue into 3Q26.
He also underscores that a favorable ABCL635 profile—showing target engagement, clean safety (especially on liver findings), and efficacy on par with existing oral NK3R agents but with once-monthly dosing—could unlock a multibillion-dollar market opportunity and fundamentally reshape the company’s growth outlook. In addition, he notes that AbCellera’s strong balance sheet, operating efficiency supported by Canadian incentives, and additional pipeline assets (including ABCL575 and new programs slated for 2027) provide further upside and risk mitigation, supporting his constructive view on the stock.
According to TipRanks, Seigerman is a 5-star analyst with an average return of 9.0% and a 52.11% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Merck & Company, and Eli Lilly & Co.
In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $11.00 price target.